NCT01272414View on ClinicalTrials.gov

Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

February 29, 2012

Conditions
Graves Ophthalmopathy
Interventions
DRUG

Botulinum Toxin Type A

2-12 units in weekly 2u doses to effect

DRUG

Saline injection

Injection of 0.4cc 0.9% normal saline

Trial Locations (1)

M5G 1X5

Mount Sinai Hospital, Toronto

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

University of Toronto

OTHER

NCT01272414 - Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction | Biotech Hunter | Biotech Hunter